Breast Cancer Highlights: ASCO 2015
- 1. Breast Cancer Highlights- ASCO 2015 Banu Arun, M.D. Professor, Breast Medical Oncology Co-Director Clinical Cancer Genetics The University of Texas MD Anderson Cancer Center Bangkok, August, 2015
- 2. Objectives ● Her-2/neu positive ● ER positive ● Triple negative ● DCIS
- 3. Slide 2 Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 4. Phase III, randomized study of trastuzumab emtansine ± pertuzumab vs trastuzumab + taxane for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study Presented By Paul Ellis at 2015 ASCO Annual Meeting
- 5. MARIANNE Study Design Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 6. MARIANNE: Progression-Free Survival Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 7. Overall Survival (First Interim Analysis) Presented By Paul Ellis at 2015 ASCO Annual Meeting
- 8. Maintenance of Health-Related Quality of Life Presented By Paul Ellis at 2015 ASCO Annual Meeting
- 9. Overview of Adverse Events Presented By Paul Ellis at 2015 ASCO Annual Meeting
- 10. MARIANNE: Toxicities Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 11. MARIANNE: CLINICAL IMPACT Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 12. Clinical Pathway HER2+ MBC: 2015 Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 13. Future for T-DM1 Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 14. ATEMPT: Adjuvant HER2+Trial (TBCRC 033) Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 15. Slide 19 Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 16. L Gianni, T Pienkowski, Y-H Im, L-M Tseng, M-C Liu, A Lluch, <br />E Starosławska, J de la Haba-Rodriguez, S-A Im, JL Pedrini, B Poirier, <br />P Morandi, V Semiglazov, V Srimuninnimit, GV Bianchi, <br />V McNally, H Douthwaite, G Ross, P Valagussa Presented By Luca Gianni at 2015 ASCO Annual Meeting
- 17. NeoSphere: study design and objectives Presented By Luca Gianni at 2015 ASCO Annual Meeting
- 18. NeoSphere: study design and pCR results Presented By Luca Gianni at 2015 ASCO Annual Meeting
- 19. NeoSphere: Phase 2 Neoadjuvant HER2+ Study Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 20. Slide 5 Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 21. Adjuvant ExteNET Study Design Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 22. ExteNET Trial: Invasive DFS, N=2840<br /> Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 23. HERA: OS<br />(Duration Question: 2y vs 1y) Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 24. ExteNET vs ALTTO and HERA : <br />Why the discrepancy? Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 25. Safety (Adverse Events ≥10%) Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 26. CONCLUSIONS: HER2+ Breast Cancer Presented By Shanu Modi at 2015 ASCO Annual Meeting
- 27. Abstract LBA502 <br /><br /> A Double Blind Phase 3 Trial of Fulvestrant With or Without Palbociclib in Pre- and Post-menopausal Women With Hormone Receptor-positive, HER2- negative Advanced Breast Cancer That Progressed on Prior Endocrine Therapy<br />(PALOMA3 Study) Presented By Nicholas Turner at 2015 ASCO Annual Meeting
- 28. Slide 2 Presented By Nicholas Turner at 2015 ASCO Annual Meeting
- 29. Palbociclib Presented By Nicholas Turner at 2015 ASCO Annual Meeting
- 30. PALOMA3 Study Design Presented By Nicholas Turner at 2015 ASCO Annual Meeting
- 31. Study Endpoints Presented By Nicholas Turner at 2015 ASCO Annual Meeting
- 32. Adverse Events—All Cause Presented By Nicholas Turner at 2015 ASCO Annual Meeting
- 33. Primary Endpoint: PFS (ITT Population) Presented By Nicholas Turner at 2015 ASCO Annual Meeting
- 34. Summary of Key Secondary Efficacy Endpoints Presented By Nicholas Turner at 2015 ASCO Annual Meeting
- 35. Implications ● First line: Paloma-1 Letrozole +/-palpbociclib ● Second line: Bolero-2 Exemestane +/- everolimus or fulvestrant +/- everolimus ● None showed survival benefit ● Increased toxicity
- 36. TITAN: Phase 3 Study of Doxorubicin/Cyclophosphamide (AC) followed by Ixabepilone (Ixa) or Paclitaxel (Pac) in Early-Stage Triple Negative Breast Cancer Presented By Denise Yardley at 2015 ASCO Annual Meeting
- 37. Study Design Presented By Denise Yardley at 2015 ASCO Annual Meeting
- 38. Key Eligibility Criteria<br /> Presented By Denise Yardley at 2015 ASCO Annual Meeting
- 39. Hematologic Toxicity Presented By Denise Yardley at 2015 ASCO Annual Meeting
- 40. Non-Hematologic Toxicity (≥ 10%) Presented By Denise Yardley at 2015 ASCO Annual Meeting
- 41. Disease-Free Survival (N=614) Presented By Denise Yardley at 2015 ASCO Annual Meeting
- 42. Overall Survival (N=614) Presented By Denise Yardley at 2015 ASCO Annual Meeting
- 43. Conclusions Presented By Denise Yardley at 2015 ASCO Annual Meeting
- 44. Primary Results of NRG Oncology/NSABP B-35: <br />A Clinical Trial of Anastrozole vs Tamoxifen in <br />Postmenopausal Patients with DCIS Presented By Richard Margolese at 2015 ASCO Annual Meeting
- 45. Slide 5 Presented By Richard Margolese at 2015 ASCO Annual Meeting N=3,104
- 46. Slide 7 Presented By Richard Margolese at 2015 ASCO Annual Meeting
- 47. Slide 8 Presented By Richard Margolese at 2015 ASCO Annual Meeting
- 48. Slide 12 Presented By Richard Margolese at 2015 ASCO Annual Meeting
- 49. B-35: Other Secondary Endpoints Presented By Richard Margolese at 2015 ASCO Annual Meeting
- 50. Slide 14 Presented By Richard Margolese at 2015 ASCO Annual Meeting
- 51. Slide 17 Presented By Richard Margolese at 2015 ASCO Annual Meeting
- 52. B-35: Average Annual Rate and <br />Number of Uterine Cancers Presented By Richard Margolese at 2015 ASCO Annual Meeting
- 53. B-35: Thromboembolic Events Presented By Richard Margolese at 2015 ASCO Annual Meeting
- 54. B-35: Average Annual Rate and <br />Number of Osteoporotic Fractures Presented By Richard Margolese at 2015 ASCO Annual Meeting
- 55. Discussion ● NSABP-B24: Tam vs placebo: Tam better, but side effects ● B-35: AI better for ↓contralateral invasive breast cancer (CinvBC) ● DFS, OS: Same ● An option in DCIS for CinvBC prevention
- 57. Slide 1 Presented By Michael Gnant at 2015 ASCO Annual Meeting
- 58. Slide 5 Presented By Michael Gnant at 2015 ASCO Annual Meeting
- 59. Slide 6 Presented By Michael Gnant at 2015 ASCO Annual Meeting
- 60. Slide 15 Presented By Michael Gnant at 2015 ASCO Annual Meeting
- 61. Slide 16 Presented By Michael Gnant at 2015 ASCO Annual Meeting
- 62. Slide 19 Presented By Michael Gnant at 2015 ASCO Annual Meeting
- 63. Slide 20 Presented By Michael Gnant at 2015 ASCO Annual Meeting
- 64. Slide 22 Presented By Michael Gnant at 2015 ASCO Annual Meeting